Pharma
Curative Therapeutics

There are only a small number of diseases in which intervention at a single point, common across all patients, can sufficiently and persistently alter the system towards a healthy state. Most diseases consist of a complex set of dynamic failures from genetics and epigenetics to neural activity: these differ across patients, within patients and over time. Trials often fail because the models used to demonstrate effectiveness in preclinical studies don’t accurately reflect the underlying causes, which can vary substantially across diseases and patients, and endpoints in trials often measure symptoms.
Our approach to creating curative therapeutic companies focuses on four themes: effectively leveraging computational approaches to address complexity; developing therapeutics that can compute in-vivo and respond dynamically to the changing internal environment; creating better systems, models and analytics to support therapeutic discovery and development; and a focus on the root cause, including fixing and buffering molecular level damage, fixing broken or unhelpful messaging and signalling pathways, correcting errors at every level of gene expression and modifying the state of cells to drive regeneration.
Areas of venture creation:
Available opportunities
Our companies
Content

-
pharmaceuticals
-
Enedra Therapeutics
Leading Cancer Biologists and Entrepreneurs Join Enedra Therapeutics as Co-Founders
Enedra Therapeutics, a therapeutics company within the Deep Science Ventures portfolio, announces that it is adding a number of seasoned industry executives as co-founders, bringing extensive expertise in cancer biology, drug discovery and corporate strategy to the team.

-
pharmaceuticals
-
Inflammatory disease
Why are there no cures for inflammatory disease – and can tolerance solve it?
Despite tremendous unmet need, there are still no cures for inflammatory disease. Existing therapies fail for known reasons – yet nobody has thus far created therapeutics that fulfil all the necessary requirements. We need to find ways to turn off the causal upstream sources of inflammation rather than simply mopping up downstream inflammatory signals.

-
pharmaceuticals
-
Solid Tumours
Immunotherapies should work more broadly - why don’t they?
Solid tumours are the leading cause of cancer deaths globally, with limited options for treatment once the tumours reach a metastatic stage. While immunotherapy has been a promising treatment for many solid cancers, its success rate varies greatly, leaving many patients without treatment options. In this article, we explore why, and how a new therapeutic approach we're developing, could finally enable immunotherapies in solid tumours.